- The 20th edition of Eco Expo Asia opens today for four days at AsiaWorld-Expo, gathering some 340 exhibitors from 13 countries and regions- The Expo features diverse activities and product technologies in response to the Policy Address, covering three key areas – Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services- The ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’ will be held tomorrow. Government officials and representatives of quasi-governmental organisations from Belt and Road countries will share strategies for local market development, to help green companies expand their international networksHONG KONG, Oct 28, 2025 - (ACN Newswire via SeaPRwire.com) – The 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd and co-organised by the Environment and Ecology Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR), opened at AsiaWorld-Expo today and runs until 31 October. Some 340 exhibitors from 13 countries and regions are showcasing innovative green technologies and products, as well as ESG and sustainable solutions. The last day of the Expo, 31 October, will open to the public for free, to encourage sustainable living practices.Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People’s Republic of China; Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; HKTDC Executive Director Sophia Chong; and Richard Li, Executive Director of Messe Frankfurt (HK) Ltd, attended Eco Expo’s opening ceremony today.HKTDC Executive Director Sophia Chong said: “This year, we celebrate a significant milestone of the Expo - its 20th edition. This not only marks our commitment to sustainability but also underscores our ongoing mission to develop the ecosystem for driving innovation and collaboration to support the green agenda. Under the theme ‘Green Innovations for Carbon Neutrality’, Eco Expo Asia provides invaluable opportunities for the green industry. This year, once again, we are bringing together leading players from the eco sector to pave the way for a more sustainable future, in alignment with the Hong Kong SAR Government’s net zero goals.”Speaking at the opening ceremony, the Secretary for Environment and Ecology, Tse Chin-wan, said, "In the global journey towards sustainability, Hong Kong serves as a ‘super connector’. With our unique position as an international city within the Guangdong-Hong Kong Macao Greater Bay Area and a bridge between Chinese Mainland and the world, Hong Kong brings together talent, technology, and capital to foster collaboration and scale up green innovation.Global exhibitors gather to showcase innovative environmental technologiesThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-ups, alongside a joint government pavilion featuring 11 bureaux and departments, including the Environment and Ecology Bureau. Chinese Mainland delegations from Guangdong, including Guangzhou and Shenzhen, Guangxi, Hunan, Inner Mongolia and Shanghai are also joining the Expo. The ANSO Environmental Technology Industry Alliance, led by the Alliance of National and International Science Organizations for the Belt and Road Regions (ANSO), is making its debut, together with 11 mainland enterprises, showcasing technologies related to water resources and the atmospheric environment, and laying the foundation for future expansion overseas. New overseas pavilions include Italy and South Korea, while Canada, the Netherlands and Norway are returning this year.The Expo is also actively building a platform to support Hong Kong and mainland enterprises to go global and explore new opportunities in green trade, attracting buyers from Japan, Thailand, Indonesia, Malaysia, Singapore, Vietnam, Hungary and Poland to visit and source at the event. For tomorrow’s ‘Experience Sharing Forum on Promoting Environmental Business in Overseas Markets’, the Hong Kong SAR Government has invited government officials and representatives from quasi-governmental organisations from Belt and Road countries to share strategies to develop local markets. In collaboration with the Environment and Ecology Bureau, the Expo extends invitations to government service providers from the Chinese Mainland, as well as from ASEAN and Belt and Road countries, to visit and source green technologies and products.Three major green and smart areas supporting the Policy AddressEnvironmental protection has become a key policy focus in recent years. The Chinese Government recently released guidelines on advancing low-carbon transition and strengthening the development of China’s carbon trading market. This year’s Policy Address highlighted new directions in green policy in Hong Kong, including fostering green and low-carbon living environments, and expediting the application of green technologies. In line with industry development, the Expo brings together a diverse range of green tech, showcasing the latest achievements in Circular Economy and Waste Management, Green & Smart Mobility and ESG-related Services.In Circular Economy and Waste Management, Green AI Technology Limited (Booth No. 3-D38) displays its AI-powered smart sorting bin with real-time waste identification, demonstrating good recycling methods through interactive learning. Dynagreen Environmental Protection Group Co., Ltd (Booth No. 3-E30) showcases its comprehensive waste treatment project, contributing to sustainable urban development.In Green & Smart Mobility, SANY Turbo Fly Machine Limited (Booth No. 6-C26) from Hong Kong and Macao, a subsidiary of SANY Group, a leading equipment manufacturing company in the Chinese Mainland, brings its SANY Mobile Charging Power Station, which can charge two electric trucks simultaneously. CIMC Enric Investment Holding (Shenzhen) Co., Ltd. (Booth No. 3-F14), a leading manufacturer of advanced clean energy equipment, showcases innovative hydrogen and green methanol technology solutions for transportation and storage.The Expo also showcases ESG-related services. Llewellyn and Partners Company Limited (Booth No. 6-D14) displays AutoTwin, a patented AI-powered integrated management platform for the construction industry, which helps reduce building operating costs, time and carbon emissions.  XSIM AI Canada Inc.,(Booth No. 6-C23), a Canadian technology company, empowers wastewater and industrial facilities with its AI-driven system to reduce downtime and lower operational costs, while cutting carbon emissions by up to 30% .Research institutions and start-ups also play a significant role in the Expo. In addition to the return of The Chinese University of Hong Kong (Booth No. 3-G24), Lingnan University (Booth No. 6-A25) and the Hong Kong Polytechnic University Jinjiang Technology and Innovation Research Institute (Booth No. 6-A23) are joining for the first time this year. The Hong Kong Science and Technology Parks Corporation (Booth No. 3-F20) presents start-up afterNATURE (Booth No. 3-F20), which is showcasing its Deep Hexagonal Basin product. This innovation creates habitats for marine life on its surface, helping to preserve coastal biodiversity. Another start-up, Formwork IO (Booth No. 3-F20), exhibits AtmosBrick and is globally debuting AtmosTile at the Expo. These ‘carbon-negative’ building materials are designed to help reduce carbon emissions.Eco Asia Conference brings together industry leaders, focusing on construction and transportation sectorsEco Expo’s highlight event, Eco Asia Conference, began today with the Government Session. Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China, shared the country’s latest environmental policies and trends. Officials from Myanmar, Sri Lanka, the Philippines and other Belt and Road countries also elaborated on their latest green policies and projects. Another session, ‘Revolutionising with Circular Economy: From Waste to Innovative Solutions’, featured experts led by the Business Environment Council, who explored the application of circular economy concepts in business operations. The Hong Kong Circular Built Environment Guidebook is also making its debut at the Conference, providing the latest green guidelines for the construction industry.On the third day of the Expo, on 30 October, the Conference will have two main themes: ‘Building a Sustainable Future: Gearing Towards a Net-Zero Built Environment’ and ‘Green & Smart Mobility – Envisioning the Future of Transportation’. Industry leaders and experts, including Pak-cheung Chan, Deputy Director, Electrical and Mechanical Services Department, Hong Kong SAR Government, and Dr Rick Mo, Head of the Centre of Advanced Power and Autonomous Systems (APAS), Hong Kong Productivity Council, will share insights and discuss how the construction and transportation industries can build sustainable cities through effective collaboration.Other exciting activities include the FHKI Q-Mark Low Carbon Restaurant Award 2025 on 28 October, the first day of the Expo. The 6th Hydrogen Economy Forum will be held on the second day of the Expo, on 29 October. Diane Wong, JP, Under Secretary for Environment and Ecology, Hong Kong SAR Government will deliver the keynote address, while Dr Wang Ziyuan, Vice President, China Hydrogen Development and Innovation Alliance for Urban Gas will share insights on the opportunities and challenges of hydrogen energy in the Guangdong-Hong Kong-Macao Greater Bay Area. The Expo also features various seminars, including ‘Startup Edge’, which promotes the development of green start-ups, featuring presentations by start-up representatives from various environmental fields.On 31 October, Eco Expo will open to the public free of charge, to encourage public participation in environmental initiatives through a series of talks, workshops and activities. These include a seminar on the recent hot topic of extreme weather by Man Yee Chan, Chief Experimental Officer, Hong Kong Observatory, and a presentation by Ocean Park on Mission R, an initiative to protect endangered wildlife and their habitats. The public can also participate in various environmental workshops, and purchase eco-friendly products from the Green Mart.Other concurrent eventsThe Hong Kong International Outdoor and Tech Light Expo takes place from 28 to 31 October at AsiaWorld-Expo, showcasing outdoor and professional technical lighting solutions for commercial and industrial use; while the Hong Kong International Lighting Fair (Autumn Edition) opened yesterday and will run until 30 October at the Hong Kong Convention and Exhibition Centre. Free shuttle bus services are offered between these venues and other locations in the city throughout the fair period. Please refer to the following page for details:https://www.hktdc.com/event/ecoexpoasia/en/travel-to-fairground-awePhoto download: https://bit.ly/48MjH8FThe 20th Eco Expo Asia, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd, opened at AsiaWorld-Expo today and runs until 31 October, attracting some 340 exhibitors. Yu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China, Ding Zhijun, Deputy Director of the Department of Energy Conservation and Comprehensive Utilization, Ministry of Industry and Information Technology of the People’s Republic of China; Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government; Sophia Chong, HKTDC Executive Director, and other honourable guests attended the opening ceremonyYu Huiwen, Vice Minister of the Ministry of Ecology and Environment of the People's Republic of China (third left), Tse Chin-wan, Secretary for Environment and Ecology of the Hong Kong SAR Government (third right), Sophia Chong, HKTDC Executive Director (second left), and other honourable guests visited the ExpoThe Hong Kong SAR Government has invited government officials and representatives of quasi-governmental organisations from Belt and Road countries and regions, including Cambodia, Myanmar and Sri Lanka, to attend the 20th Eco Expo AsiaThis year’s Expo brings together 17 pavilions. For the first time, the Environmental Campaign Committee is hosting a pavilion, presenting 22 local green start-upsKorea is a new pavilion from overseas, with a strong lineupGreen and Smart Mobility is a new zone that has been added this year, focusing on green transport solutions and productsIndustry newcomers, such as research institutions and start-ups, bring innovative green solutionsThe Eco Asia Conference gathers global officials, industry leaders and experts to exchange insights on environmental issuesWebsiteEco Expo Asia: www.ecoexpoasia.comMedia enquiriesPlease contact the HKTDC’s Communications and Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton Lauw    Tel: (852) 2584 4472  Email: clayton.y.lauw@hktdc.orgThe HKTDC’s Media Room: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Messe FrankfurtThe Messe Frankfurt Group is one of the world’s leading trade fair, congress and event organisers with its own exhibition grounds. With a workforce of some 2,160 people at its headquarters in Frankfurt am Main and in 28 subsidiaries, it organises events around the world. Group sales in financial year 2022 were around €454 million. We serve our customers’ business interests efficiently within the framework of our Fairs & Events, Locations and Services business fields. One of Messe Frankfurt’s key strengths is its powerful and closely knit global sales network, which covers around 180 countries in all regions of the world. Our comprehensive range of services – both onsite and online – ensures that customers worldwide enjoy consistently high quality and flexibility when planning, organising and running their events. We are using our digital expertise to develop new business models. The wide range of services includes renting exhibition grounds, trade fair construction and marketing, personnel and food services. Sustainability is a central pillar of our corporate strategy. Here, we strike a healthy balance between ecological and economic interests, social responsibility and diversity.For more information, please visit our website at: www.messefrankfurt.com/sustainability. With its headquarters in Frankfurt am Main, the company is owned by the City of Frankfurt (60%) and the State of Hesse (40%). For more information, please visit our website at: www.messefrankfurt.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Rouyn-Noranda, Quebec--(ACN Newswire via SeaPRwire.com - October 28, 2025) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce assay results from fifteen new drill holes completed at its 100%-owned O'Brien Gold Project ("O'Brien" or the "Project") located in the Abitibi region of Québec. The fifteen holes represent step-outs below the existing geological model and the historic O'Brien Gold Mine and are part of an ongoing 140,000-metre drill program designed to test the overall scope of gold mineralization at the Project (see Radisson news release dated October 16, 2025). All holes intersected gold mineralization in characteristic quartz-sulphide-gold veins within alteration zones, and thirteen of the holes returned intercepts with grades and thicknesses consistent with the Project's existing mineral resources.Today's results include significant intercepts in three separate step-out locations (Figures 1 & 2), each of which has significance for the potential future growth of the Project's mineral resources. These are:Between Trends #1 and #2 at 1,000 Metres Vertical DepthOB-25-371W5 intersected 10.50 grams per tonne ("g/t") gold ("Au") over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metreOB-25-371W4 intersected 11.25 g/t Au over 2.5 metres, including 17.80 g/t Au over 1.5 metresOB-25-371W6 intersected 4.51 g/t Au over 9.0 metres, including 10.70 g/t Au over 1.5 metresBeneath the Historic "O'Brien Mine West" at 1,000 Metres Vertical Depth OB-25-376W1 intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metresOB-25-376 intersected 8.05 g/t Au over 2.50 metres, including 15.75 g/t Au over 1.0 metreBeneath the Historic "O'Brien Mine" at 1,100 Metres Vertical DepthOB-24-337W11 intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metresMatt Manson, President & CEO, commented: "Today's drill results illustrate the extension of classic, high-grade O'Brien gold mineralization across a broad front. We are reporting the first high-grade intercepts beneath the western portion of the historic mine, with drill hole OB-25-376W1 extending mineralization 160 metres below the former mine in this area. Drill hole OB-24-337W11 demonstrates continuity of high-grade mineralization below the main stope of the historic mine. Of particular note, drill holes OB-25-371W4 to W6 returned high-grade mineralization on the western edge of the deep extension of Trend #2, close to the observed extension of Trend #1 (Figures 1&2). This suggests that the apparent gap between these two trends is a function of drill coverage rather than geology, as we have suspected. Closing this gap with new drilling is a priority. With a fully-funded 140,000-metre drill program ongoing and an increase in rigs from the current four to an eventual eight, we are casting a wide net at O'Brien and seeing consistent success."Figure 1: Longitudinal Vertical Section and Plan View of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Today's Drill Holes IllustratedTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_002full.jpgNotes on Calculation of Drill Intercepts:The O'Brien Gold Project Mineral Resource Estimate effective May 6, 2025 ("MRE") utilizes a 2.20 g/t Au bottom cut-off, a US$2,000 gold price, a minimum mining width of 1.2 metres, and a 40 g/t Au upper cap on composites. Intercepts presented in Table 1 are calculated with a 3.00 g/t Au bottom cut-off. True widths, based on depth of intercept and drill hole inclination, are estimated to be 30-80% of core length. Table 2 presents additional drill intercepts calculated with a 1.00 g/t bottom cut-off over a minimum 1.0 metre core length so as to illustrate the frequency and continuity of mineralized intervals within which high-grade gold veins at O'Brien are developed. Lithology Codes: PON-S3: Pontiac Sediments; V3-S, V3-N, V3-CEN: Basalt-South, North, Central; S1P, S3P: Conglomerate; POR-S, POR-N: Porphyry South, North; TX: Crystal Tuff; ZFLLC: Larder Lake-Cadillac Fault Zone.Figure 2: Longitudinal Vertical Section of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Deep Step-Out Drill Holes Completed and/or Published by the Company since December 2024. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_004full.jpgGold Mineralization at O'BrienGold mineralizing quartz-sulphide veins at O'Brien occur within a thin band of interlayered mafic volcanic rocks, conglomerates, and porphyritic andesitic sills of the Piché Group occurring in contact with the east-west oriented Larder Lake-Cadillac Break ("LLCB"). Gold, along with pyrite and arsenopyrite, is typically associated with shearing and a pervasive biotite alteration, and developed within multiple Piché Group lithologies and, occasionally, the hanging-wall Pontiac and footwall Cadillac meta-sedimentary rocks.As mapped at the historic O'Brien mine, and now replicated in the modern drilling, individual veins are generally narrow, ranging from several centimetres up to several metres in thickness. Multiple veins occur sub-parallel to each other, as well as sub-parallel to the Piché lithologies and the LLCB. Individual veins have well-established lateral continuity, with near-vertical, high-grade shoots developed over significant lengths. Based on the historic data available, it is clear that the former mine was "high-graded", with mining focussed on a main central stope and parallel veins identified but left undeveloped.The historic O'Brien mine produced over half a million ounces of gold from such veins and shoots at an average grade exceeding 15 g/t Au and over a vertical extent of at least 1,000 metres. Modern exploration has focussed on delineating well developed vein mineralization to the east of the historic mine, with additional high-grade shoots becoming evident in the exploration data over what has been described as a series of repeating trends ("Trend #s 0 to 5").Step-Out Drilling at O'BrienSince the end of 2024, Radisson has been pursuing a program of broad step-outs beneath the historic O'Brien Gold mine and the existing mineral resources designed to test the extent of mineralization at the Project. This drilling is accomplished with pilot holes followed by wedges and directional drilling to maximize drill efficiency. On October 16, 2025 Radisson announced the expansion of the step-out drill program to 140,000 metres employing an eventual eight drill rigs.The origin of the step-out drill program was the deep pilot hole OB-24-337, which was the first exploration drill hole located below the former mine workings since mining ended in 1957. This hole intersected 31.24 g/t Au over 8.0 metres, including 242.0 g/t Au over 1.0 metre at approximately 1,500 metres vertical depth (see Radisson news release dated December 16, 2024). With today's results, assay results from a total of 11 wedges from OB-24-337 have now been reported and up to six gold-bearing veins have been delineated over an area of approximately 250 metres (east-west) by 500 metres (vertical). Included in today's results is the eleventh wedge, OB24-337-W11, which intersected 7.00 g/t Au over 3.0 metres, including 12.60 g/t Au over 1.5 metres, and 13.00 g/t Au over 1.50 metres approximately 100 metres below the final historic mining stope (Figure 1). This serves to demonstrate the continuity of mineralization from the former mine downwards towards the cluster previously published wedges (Figures 1 & 2; see Radisson news release dated July 16, 2025). Current drilling in this area is focussed on infilling with pilot holes and wedge extensions both above and below the OB-24-337 pattern of wedge branches to test the full continuity of mineralization from the historic mine down to 2 kilometres depth.Step-out drilling with wedge branches has also confirmed high-grade mineralization 170 metres below the base of the existing mineral resources at Trend #1 and 300 metres at Trend #2. These have included pilot hole OB-24-324, which intersected 27.61 g/t Au over 6.0 metres at Trend #1 (see Radisson news release dated October 30, 2024) and OB-24-363, which intersected 8.41 g/t Au over 2.20 metres, including 14.40 g/t Au over 1.20 metres and 9.07 g/t Au over 1.80 metres, including 12.10 g/t Au over 0.90 metres at Trend #2 (see Radisson news release dated September 8, 2025). Today's results include six wedges from drill hole OB-25-371, which demonstrate strongly developed, high-grade mineralization on the western edge of the deep extension of Trend #2. These holes include OB-25-371W5, which intersected 10.50 g/t Au over 6.5 metres, including 14.90 g/t Au over 1.5 metres and including 16.95 g/t Au over 1.0 metre (Figures 1&3). The significance of these holes is that the apparent separation of Trend #1 and Trend #2 is based, in part, on a data gap caused by drill rig access restrictions and a lack of drilling (Figure 2). Targeting this gap and testing for continuity of mineralization between Trends #1 and #2, as well as at depth, is a priority of the current drill program.Today's results also include the first drill holes located below the western portion of the historic O'Brien Gold Mine, designated "O'Brien Mine West". As with the main mining area, no exploration had been conducted below O'Brien Mine West since operations ended in 1957. From pilot hole OB-25-376 and wedge branches W1 to W5, five holes returned intercepts with grades and thicknesses consistent with the Project's mineral resources, including OB-25-376W1, which intersected 9.16 g/t Au over 2.5 metres, including 14.70 g/t Au over 1.1 metres (Figure 1). This now extends gold mineralization at O'Brien Mine West 160 metres below the base of the former mine workings (Figure 4).Figure 3: Vertical Cross Section through "Trend #2" with Drill Hole Wedges OB-25-371W2 to W6To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_005full.jpg Figure 4: Vertical Cross Section through "O'Brien Mine West" with Drill Hole OB-25-376 and Wedges W1 to W5To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10977/272164_3fafb92ae4c30b1d_006full.jpgQA/QCAll drill cores in this campaign are NQ in size. Assays were completed on sawn half-cores, with the second half kept for future reference. The samples were analyzed using standard fire assay procedures with Atomic Absorption (AA) finish at ALS Laboratory Ltd, in Val-d'Or, Quebec. Samples yielding a grade higher than 10 g/t Au were analyzed a second time by fire assay with gravimetric finish at the same laboratory. Mineralized zones containing visible gold were analyzed with metallic sieve procedure. Standard reference materials, blank samples and duplicates were inserted prior to shipment for quality assurance and quality control (QA/QC) program.Qualified Persons Disclosure of a scientific or technical nature in this news release was prepared under the supervision of Mr. Richard Nieminen, P.Geo, (QC), a geological consultant for Radisson and a Qualified Person for purposes of NI 43-101. Mr. Luke Evans, M.Sc., P.Eng., ing, of SLR Consulting (Canada) Ltd., is the Qualified Person responsible for the preparation of the MRE at O'Brien. Each of Mr. Nieminen and Mr. Evans is independent of Radisson and the O'Brien Gold Project.About Radisson MiningRadisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 Preliminary Economic Assessment described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.58 million ounces (2.20 million tonnes at 8.2 g/t Au), with additional Inferred Mineral Resources estimated at 0.93 million ounces (6.67 million tonnes at 4.4 g/t Au). Please see the NI 43-101 "O'Brien Gold Project Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025, and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the O'Brien Gold Project. For more information on Radisson, visit our website at www.radissonmining.com or contact:Matt MansonPresident and CEO416.618.5885mmanson@radissonmining.comKristina PillonManager, Investor Relations604.908.1695kpillon@radissonmining.comForward-Looking StatementsThis news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the ability to execute the Company's plans relating to the O'Brien Gold Project as set out in the Preliminary Economic Assessment; the Company's ability to complete its planned exploration and development programs; the absence of adverse conditions at the O'Brien Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the O'Brien Gold Project profitable; the Company's ability to continue raising necessary capital to finance its operations; the ability to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies; local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; planned and ongoing drilling; the significance of drill results; the ability to continue drilling; the impact of drilling on the definition of any resource; and the ability to incorporate new drilling in an updated technical report and resource modelling; the Company's ability to grow the O'Brien Gold Project; and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others; the risk that the O'Brien Gold Project will never reach the production stage (including due to a lack of financing); the Company's capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company's activities; price volatility and availability of commodities; instability in the global financial system; the effects of high inflation, such as higher commodity prices; the risk of any future litigation against the Company; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; risks relating to the drill results at O'Brien; the significance of drill results; and the ability of drill results to accurately predict mineralization. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release.Please refer to the "Risks and Uncertainties Related to Exploration" and the "Risks Related to Financing and Development" sections of the Company's Management's Discussion and Analysis dated April 29, 2025 for the year ended December 31, 2024, and the Company's Management's Discussion and Analysis dated August 27, 2025 for the three-month period ended June 30, 2025, all of which are available electronically on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272164 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - The International Leo Tolstoy Peace Prize Jury announced the 2025 laureates in recognition of outstanding efforts contributing to regional harmony and security in Central Asia. The award honors the signing of the Treaty on the Junction Point of State Borders and the Khujand Declaration of Eternal Friendship in Khujand, Tajikistan, on March 31, 2025 — landmark agreements that strengthen legal frameworks for mutual trust and cross-border collaboration.Established on June 22, 2022, by the Russian Historical Society, the Russian Peace Foundation, and the Russian Military Historical Society, the International Leo Tolstoy Peace Prize Foundation convenes juries including prominent figures from Argentina, Belarus, India, China, Russia, France, South Africa, and Japan. Jury Chairman Valery Gergiev, renowned conductor and artistic director of the Mariinsky Theatre, emphasized the prize’s mission to “advance global understanding and mutual respect.” He noted the growing reach of the peace movement inspired by Russian writer-philosopher Leo Tolstoy, expressing hope that the prize could, like music, “help nations listen and truly hear one another.”The 2025 honor celebrates the joint efforts of:- Sadyr Japarov, Kyrgyz Republic- Emomali Rahmon, Republic of Tajikistan- Shavkat Mirziyoyev, Republic of UzbekistanTheir collaboration has strengthened stability, sustainable growth, and the international profile of Central Asia. The award ceremony date will be announced soon.About the PrizeThe International Leo Tolstoy Peace Prize is awarded by an international jury established by the founders of the L.N. Tolstoy International Peace Prize Foundation. The jury is composed of distinguished Russian and foreign figures of recognized international standing and moral authority.Candidates for the Prize may include individuals, initiative groups, national and international public foundations, organizations, movements, scientific and research centers, as well as educational institutions. Self-nomination is not permitted; however, nominators are encouraged to publicly discuss the candidates they propose. Rooted in the humanist ideals of Leo Tolstoy, the Prize honors those whose work embodies the pursuit of peace, moral integrity, and shared progress for humanity.Media contactOrganization: The International Leo Tolstoy Peace PrizeContact: Media teamWebsite: https://tolstoypeaceprize.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics"ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."CIL's global manufacturing network, including facilities in North America, Europe, and Asia, enables CIL to provide a diversified and resilient supply chain for pharmaceutical partners. Every ISOAPI-D product is manufactured in ISO 9001-certified facilities, ensuring the highest standards of quality, regulatory compliance, and full traceability throughout the production process.A core component of the ISOAPI-D line is heavy water (D₂O), which is sourced exclusively from approved suppliers. This product is fully traceable and tritium-free, aligning with stringent safety and regulatory requirements of the pharmaceutical industry.The ISOAPI-D range also features advanced intermediates that allow for more streamlined synthetic pathways. By reducing the number of synthesis steps and optimizing production efficiency, these intermediates can help lower manufacturing costs and accelerate the time to market for new therapeutics.Since 1981, CIL has been a trusted supplier of premium deuterated materials to leading pharmaceutical and biotechnology companies worldwide. This longstanding commitment to quality and reliability continues with the launch of ISOAPI-D, offering customers a secure, high-quality supply of essential reagents and reducing operational risk in their development pipelines."ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation," said Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL. "Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."Visit CIL at CPhI Frankfurt, Stand #2.0G2, October 28-30, to discover ISOAPI-D, the future of deuterated chemistry for pharmaceuticals.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds.Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com